Xiidra has
~90% overall coverage
for commercial and Medicare Part D patients nationwide1*
Xiidra has
Commercial
Xiidra coverage exceeds Restasis® in most major plans1†
Pay as little as $0
With Xiidra, eligible commercial patients may pay $0 for their first Rx2‡
Medicare Part D
Xiidra offers equal coverage to Restasis® in most major plans3
We've got you and your patients covered
ELIGIBLE COMMERCIAL Patients may pay as little as
When using the Xiidra Co-pay Card, ~90% of eligible commercial patients paid $02‡
Is your patient experiencing financial hardship?
For patients who have limited or no prescription coverage, contact 1-877-4XiiDRA (1-877-494-4372) or visit www.patientassistance.bausch.com. Patients who are eligible may receive their medication for free
Additional questions about cost and affordability?
For more on helping patients start and stay on Xiidra, and information on Xiidra's $0 Co-Pay Program for commercially eligible patients or the Insider Support Program, please call the Xiidra Access Program at 1-877-4XiiDRA (1-877-494-4372)
There are additional ways to help patients save
BlinkRx assists with prior authorizations and more, offering a seamless experience for your practice and patients
Prior Authorization Support
BlinkRx services provide prior authorization support for Xiidra prescriptions, should your patients’ insurance require it
Low Price
BlinkRx works with your eligible commercially insured patients’ insurance and applies available savings to their Xiidra prescription, with no co-pay card needed
Free and Fast Delivery
BlinkRx delivers Xiidra prescriptions for free from one of their licensed network pharmacies around the country
Simple Patient Experience
BlinkRx will send patients a text with the lowest available price so that they can immediately purchase their Xiidra prescription online or over the phone
Ample Stocking
BlinkRx services the entire country, making Xiidra accessible for all patients
Dedicated Customer Support
BlinkRx has a team of pharmacists and technicians that are available to support you, your team, and your patients from onboarding to adherence
Want to learn more about BlinkRx?
Find a helpful guide and additional downloadable resources
Need Prior Authorization Support?
Being proactive in the prior authorization process may help improve your patients’ success with Xiidra
Help Patients Start and Stay on Xiidra
Send patients home with the materials they need for a smooth onboarding process
*Based on data from April 2024. Up to 95% of commercial and 71% of Medicare Part D patients may be covered.
†Plan limitations may apply.
‡Terms and conditions apply. For the first 30-day, 60-day, or 90-day prescription. Subject to benefit limitations. Visit Xiidra.com for complete terms and conditions.
Indication and important safety information
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
- Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
- In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
- To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
- Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
- Safety and efficacy in pediatric patients below the age of 17 years have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information for Xiidra.
References
- Data on file. MMIT Portal, April 2024. Bausch & Lomb Inc.
- Data on file. ConnectiveRx Xiidra Savings Card Co-pay as of 2024. Bausch & Lomb Inc.
- Data on file. MMIT Portal, February 2024. Bausch & Lomb Inc.
Indication and important safety information
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
- Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
- In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced